Treatment of the elderly colorectal cancer patient: SIOG expert recommendations

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 5-16

  Papamichael, Demetris ^a   Audisio, R ^b   Horiot, J C ^c   Glimelius, B ^d   Sastre, J ^e   Mitry, E ^f   Van Cutsem, E ^g   Gosney, M ^h   Kohne C H ⁱ   Aapro, M ^j  

^a Department of Medical Oncology   (Cyprus)

^b WHISTON HOSPITAL   (United Kingdom)

^c Service de Radiotherapie   (France)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f Service d'Hépato gastroentérologie et Oncologie Digestive   (France)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF READING   (United Kingdom)

ⁱ KLINIKUM OLDENBURG   (Germany)

^j CLINIQUE DE GENOLIER   (Switzerland)

more..

Author keywords

Chemotherapy; Colorectal cancer; Elderly; Geriatric; Radiotherapy; Surgical management

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; UFT;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; BLEEDING; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELDERLY CARE; GERIATRIC ASSESSMENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; METASTASIS; NEUTROPENIA; PREOPERATIVE EVALUATION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; RECURRENT CANCER; REVIEW; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HEALTH PLANNING GUIDELINES; HUMANS; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; SOCIETIES, MEDICAL;

EID: 58949089717     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn532     Document Type: Review

References (132)

1. Aapro MS, Kohne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005; 10: 198-204.
2. Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-1338.
3. Berrino F, Capoccaccia R, Esteve J, Gatta G. Survival of Cancer Patients in Europe: The EUROCARE-2 Study. Lyon: IARC 1999.
4. Biganzoli L, Aapro M. Adjuvant chemotherapy in the elderly. Ann Oncol 2003; 14 (Suppl 3): Iii1-iii3.
5. Surbone A, Kagawa-Singer M, Terret C, Baider L. The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 2007; 18: 633-638.
6. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
7. Andre T, Tournigand C, Achille E et al. Adjuvant treatment of colon cancer MOSAIC study's main results. Bull Cancer 2006; 93 (Suppl 1): S5-S9.
8. Surgery for colorectal cancer in elderly patients: A systematic review. Colorectal Cancer Collaborative Group. Lancet 2000; 356: 968-974.
9. Neugut AI, Matasar M, Wang X et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375.
10. Potosky AL, Harlan LC, Kaplan RS et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20: 1192-1202.
11. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857.
12. Sundararajan V, Mitra N, Jacobson JS et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357.
13. Damhuis RA, Wereldsma JC, Wiggers T. The influence of age on resection rates and postoperative mortality in 6457 patients with colorectal cancer. Int J Colorectal Dis 1996; 11: 45-48.
14. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067.
15. Mitry E, Bouvier AM, Esteve J, Faivre J. Improvement in colorectal cancer survival: A population-based study. Eur J Cancer 2005; 41: 2297-2303.
16. Guyot F, Faivre J, Manfredi S et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005; 16: 756-761.
17. Kronborg O. Colonic screening and surveillance. Best Pract Res Clin Gastroenterol 2001; 15: 301-316.
18. Kronborg O. Faecal occult blood testing in the secondary prevention of colorectal cancer. Eur J Cancer Prev 2001; 10: 167-168.
19. Scholefield JH, Moss S, Sufi F et al. Effect of faecal occult blood screening on mortality from colorectal cancer; results from a randomised controlled trial. Gut 2002; 50: 840-844.
20. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477.
21. Robinson MH, Hardcastle JD, Moss SM et al. The risks of screening: Data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999; 45: 588-592.
22. Scholefield JH, Robinson MH, Mangham CM, Hardcastle JD. Screening for colorectal cancer reduces emergency admissions. Eur J Surg Oncol 1998; 24: 47-50.
23. Steine S, Laerum E. Referrals for radiological examination of the large bowel. Pre-radiological examinations, tests and referral letters. Fam Pract 1994; 11: 21-25.
24. Steine S, Stordahl A, Lunde OC et al. Double-contrast barium enema versus colonoscopy in the diagnosis of neoplastic disorders: Aspects of decision-making in general practice. Fam Pract 1993; 10: 288-291.
25. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-1300.
26. Levin TR, Farraye FA, Schoen RE et al. Quality in the technical performance of screening flexible sigmoidoscopy: Recommendations of an international multi-society task group, Gut 2005; 54: 807-813.
27. Cardin F, Barbato B, Terranova O. Outcomes of safe, simple colonoscopy in older adults. Age Ageing 2005; 34: 513-515.
28. Regula J, Rupinski M, Kraszewska E et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006; 355: 1863-1872.
29. Syn WK, Tandon U, Ahmed MM. Colonoscopy in the very elderly is safe and worthwhile. Age Ageing 2005; 34: 510-513.
30. Pickhardt PJ. Virtual colonoscopy for primary screening. The future is now. Minerva Chir 2005; 60: 139-150.
31. Sonnenberg A, Delco F, Bauerfeind P. Is virtual colonoscopy a cost-effective option to screen for oolorectal cancer? Am J Gastroenterol 1999; 94: 2268-2274.
32. CT colonography ("virtual colonoscopy") for colon cancer screening. Technol Eval Cent Asses Program Exec Summ 2004; 19: 1-3.
33. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: Computed tomographic colonography. Ann Intern Med 2005; 142: 635-650.
34. Pickhardt PJ. Three-dimensional endoluminal CT colonography (virtual colonoscopy): Comparison of three commercially available systems. Am J Roentgenol 2003; 181: 1599-1606.
35. Malone DE, McGrath FP. Optimizing the detection of colorectal liver metastases within the Canadian health care system. Can Assoc Radiol J 1993; 44: 5-13.
36. Zerhouni EA, Rutter C, Hamilton SR et al. CT and MR imaging in the staging of colorectal carcinoma: Report of the Radiology Diagnostic Oncology Group II. Radiology 1996; 200: 443-451.
37. Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol 2005; 6: 790-797.
38. Whynes DK, Frew EJ, Edwards R, Atkin WS. Costs of flexible sigmoidoscopy screening for colorectal cancer in the United Kingdom. Int J Technol Assess Health Care 2003; 19: 384-395.
39. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer: Is it cost-effective? Health Econ 1998; 7: 21-29.
40. Lejeune C, Arveux P, Dancourt V et al. Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer. Int J Technol Assess Health Care 2004; 20: 434-439.
41. Whynes DK, Frew EJ, Manghan CM et al. Colorectal cancer, screening and survival: The influence of socio-economic deprivation: Public Health 2003; 117: 389-395.
42. Koroukian SM, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 2006; 24: 2304-2310.
43. Extermann M, Aapro M, Bemabei R et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.
44. Bouvier AM, Launoy G, Lepage C, Faivre J. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther 2005; 22: 233-241.
45. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg 2002; 89: 1557-1562.
46. Damhuis RA, Meurs CJ, Meijer WS. Postoperative mortality after cancer surgery in octogenarians and nonagenarians: Results from a series of 5,390 patients. World J Surg Oncol 2005; 3: 71.
47. Kiran RP, Pokala N, Dudrick SJ. Long-term outcome after operative intervention for rectal cancer in patients aged over 80 years: Analysis of 9,501 patients. Dis Colon Rectum 2007; 50: 604-10.
48. Manfredi S, Bouvier AM, Lepage C et al. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115-1122.
49. Fallahzadeh H, Mays ET. Preexisting disease as a predictor of the outcome of colectomy. Am J Surg 1991; 162: 497-498.
50. Audisio RA, Veronesi P, Ferrario L et al. Elective surgery for gastrointestinal tumours in the elderly. Ann Oncol 1997; 8: 317-326.
51. Mazzoni G, Tocchi A, Miccini M et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients. Int J Colorectal Dis 2007; 22: 77-83.
52. Menon KV, Al-Mukhtar A, Aldouri A et al. Outcomes after major hepatectomy in elderly patients. J Am Coll Surg 2006; 203: 677-683.
53. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221.
54. de Liguori Carino N, van Leeuwen BL, Ghaneh P et al. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Haematol 2008 (in press).
55. Ramesh HS, Pope D, Gennari R, Audisio RA. Optimising surgical management of elderly cancer patents. World J Surg Oncol 2005; 3: 17.
56. Ramesh HS, Jain S, Audisio RA. Implications of aging in surgical oncology. Cancer J 2005; 11: 488-94.
57. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performamce status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
58. Nickelsen TN, Jorgensen T, Kronborg O. Lifestyle and 30-day complications to surgery for colorectal cancer. Acta Oncol 2005; 44: 218-223.
59. Audisio RA, Pope D, Ramesh H et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help: A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008; 65: 156-163.
60. Heriot AG, Tekkis PP, Smith JJ et al. Prediction of postoperative mortality in elderly patients with colorectal cancer. Dis Colon Rectum 2006; 49: 816-824.
61. Heald RJ, Moran BJ, Ryall RD et al. Rectal cancer: The Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133: 894-899.
62. Folkesson J, Birgisson H, Pahlman L et al, Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650.
63. Gerard JP, Romestaing P, Ardiet JM, Momex F. Endocavity radiation therapy. Semin Radiat Oncol 1998; 8: 13-23.
64. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980-987.
65. Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group. Ann Surg Oncol 1996; 3: 423-430.
66. Kapiteijn E, Kranenbarg EK, Steup WH et al. Total mesorectal excision (TIME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J Surg 1999; 165; 410-420.
67. Delaney CP, Lavery IC, Brenner A et al. Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers. Ann Surg 2002; 236: 203-207.
68. O'Connell JB, Maggard MA, Liu JH et al. Are survival rates different for young and older patients with rectal cancer? Dis Colon Rectum 2004; 47: 2064-2069.
69. Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 1995; 75: 2269-2275.
70. Marijnen CA, Kapiteijn E, van de Velde CJ et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20; 817-825.
71. Marijnen CA, Nagtegaal ID, Kapiteijn E et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 1311-1320.
72. Marijnen CA, van de Velde CJ, Putter H et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847-1858.
73. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223.
74. Sebag-Montefiore D, Steele R, Ouirke P et al. Routine short-course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. J Clin Oncol 2006: 18S (Abstr 3511).
75. Radu C, Berglund K, Pählman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol 2008; 87: 343-9.
76. Ask A, Johansson B, Glimelius B. The potential of proton beam radiation therapy in gastrointestinal cancer. Acta Oncol 2005; 44: 896-903.
77. Widder J, Herbst F, Scheithauer W. Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer. Acta Oncol 2,005; 44: 921-923.
78. Sargent DJ, Goldberg RM, Jacobson SD et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patents. N Engl J Med 2001; 345: 1091-1097.
79. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711.
80. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-1743.
81. Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-234.
82. Twelves C, Scheithauer W, McKendrick J et al. Capecitabine versus 5-FU/ LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. ASCO Gastrointestinal Cancers Symposium http://www.asco.org/2008 (Abstr 274).
83. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
84. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418.
85. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
86. Quasar Collaborative G, Gray R, Bamwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370: 2020-2029.
87. Beretta G, Bollina R, Cozzi C, Beretta G. Should we consider weekly (w) chemotherapy with 5-fluorouracil (F) + racemic folinic acid (f) a standard treatment for carcinoma of the digestive tract (DTD) in elderly patients. Proc Am Soc Clin Oncol 1997 (Abstr 920).
88. Mitry E, Douillard JY, Van Cutsem E et al. Predictive factors of survival in patients with advanced colorectal cancer: An individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-1017.
89. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as ffrst-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
90. Kohne CH, van Cutsem E, Wlls J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
91. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
92. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
93. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
94. de Gramont A, Figer A, Seymour M et al. Leocovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
95. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
96. Rosati G, Cordio S, Tucci A et al. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients. Oncology 2005; 69: 122-129.
97. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23: 3545-3551.
98. Twelves CJ, Butts CA, Cassidy J et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005; 5: 101-107.
99. Seymour MT, Maughan TS, Wasan HS et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. J Clin Oncol 2007; 25: (Abstr 9030).
100. Mitry E, Phelip JM, Bonnetain F et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): Results of a planned interim analysis. ASCO Gastrointestinal Cancers Symposium www.asco.org 2008 (Abstr 281).
101. Kozloff MF, Sugrue MM, Purdie DM et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in eldedy patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol 2008; 26 (Suppl): (Abstr 4026).
102. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus idnotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
103. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
104. Saltz LB, Meropol NJ, Loehrer PJ Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
105. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FUJ/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
106. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
107. Lenz HJ, Mayer RJ, Mirtsching B et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: (Abstr 3536).
108. Pessino A, Artale S, Guglielmi A et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 2008; 19(4): 711:716.
109. Bouchahda M, Macarulla T, Spano JP et al. Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderty patients with extensively pre-treated metastatic colorectal cancer. Crit Rev Oncol Hematol 2008; 67: 255-262.
110. Sastre J, Aranda E, Gravalos C et al. Single-agent cetuximab as first-line treatment for elderly patents with advanced-colorectal cancer: Preliminary results of a TTD phase II study. Ann Oncol 2006; 17: (Abstr 3240).
111. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
112. Cutsem Van, Lang I, D'haens G et-al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (Suppl): (Abstr 2).
113. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
114. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
115. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
116. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520; discussion 520-522.
117. Adam R. Chemotherapy and surgery: New perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 (Suppl 2): Ii13-ii16.
118. Tabernero J, Van Cutsem E, Díaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232.
119. Fisher GA, Kuo T, Cho CD et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22(14S): (Abstr 3514).
120. Folprecht G, Lutz MP, Schoffski P et al. Celuximab and irinotecan/ 5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-6.
121. Kopetz S, Abbruzzese JL, Eng C et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). J Clin Oncol 2006; 24(18S): (Abstr 3579).
122. Peeters M, Raoul Y, Van Laetham J-L et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer. Eur J Cancer Suppl 2005; 3: (Abstr 664).
123. Abad A, Massuti B, Anton A et al. Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol 2008; 47: 286-292.
124. Falcone A, Masi G, Murr R et al. Biweekly irinotecan, oxaliplatin, and infusional 5+U/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic CRC (MCRC). ASCO Gastrointestinal Cancers Symposium http://www.asco.org/2006 (Abstr 227).
125. Quenet F, Nordlinger B, Rivoire M et al. Resection of previously unresectable liver metastatses from colorectal cancer (LMCRC) after chemotherapy (CT) with GPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. J Clin Oncol 2004; 22(14S): (Abstr 3613).
126. Seium Y, Stupp R, Ruhstaller T et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: A phase I-II study. Ann Oncol 2005; 16: 762-766.
127. Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
128. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
129. Adam R, Laurent C, Poston G et al. Liver resection of colorectal metastases in elderly patients: Is it worthwhile and is there an age limit? ASCO Gastrointestinal Cancers Symposium www.asco.org 2008 (Abstr 452).
130. Trimble EL, Christian MC. Cancer treatment and the older patient. Clin Cancer Res 2006; 12: 1956-1957.
131. Muss HB, Biganzoli L, Sargent DJ, Aapro M. Adjuvant therapy in the elderly: Making the right decision. J Clin Oncol 2007; 25: 1870-1875.
132. Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol 2007; 25: 1891-1897.